Alimta Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Drug: Cadonilimab;   Drug: Pemetrexed;   Drug: Carboplatin Sponsors:   Qian Chu;   Akeso Pharmaceuticals, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 21, 2023 Category: Research Source Type: clinical trials

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
Condition:   Locally Advanced or Metastatic NSCLC Interventions:   Drug: AK104;   Drug: Tislelizumab;   Drug: carboplatin;   Drug: Pemetrexed;   Drug: Paclitaxel Sponsor:   Akeso Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials